China Seen Benefiting From U.S. FDA Ban On 30 Ranbaxy Drugs
This article was originally published in PharmAsia News
Executive Summary
China could be the main beneficiary of the U.S. ban on 30 Ranbaxy Laboratories drugs, say analysts in China. One said Chinese drug makers are in line to take the market sector in the United States that Ranbaxy could lose by the ban. Pharmas in China have been increasing their own production, and the country's regulatory requirements are expected to help Chinese pharmaceuticals gain a share of India's U.S. market. Another notes China's leadership in making active pharmaceutical ingredients used by most drug makers. (Click here for more
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.